April, Author at Kheiron Medical

An artificial intelligence (AI) breast screening solution called Mia helped doctors find an additional 12% more cancers than in routine practice, as announced today by Kheiron Medical Technologies, NHS Grampian, the University of Aberdeen and Microsoft. If deployed across the entire NHS, a 12% uplift in the detection of breast cancer could lead to better outcomes for thousands of women across the UK. The augmented AI workflow also showed a decrease in women recalled unnecessarily for further assessment and modelled a workload reduction of up to 30%.

More than two million women are screened for breast cancer each year in the UK, but breast cancer is extremely hard to detect. About 20% of women with breast cancer have tumours that are missed by mammogram screening, which is why many countries mandate that two radiologists should read every mammogram.

NHS Grampian, which provides health and social care services to more than 500,000 people in the North East of Scotland, conducted the first formal prospective evaluation of Kheiron’s Mia AI solution (CE Mark class IIa) in the UK as part of a study with 10,889 patients.

Through this evaluation, which was funded by a UK Government ‘AI in Health and Care Award’, Mia helped medical staff detect more cancers. The earlier detection of primarily high-grade cancers has enabled earlier treatment, which has a greater likelihood of success. The evaluation also showed no increase in the number of women called back unnecessarily for further investigation because of false positives. As part of a simulated workflow with AI augmentation, a workload reduction of up to 30% was modelled.

Barbara, [Aberdeen], was one of the first women in the UK to have her cancer detected by Mia. “My cancer was so small that the doctors said it would not have been picked up by the human eye,” said Barbara. Because her cancer was picked up at an earlier stage before spreading. Barbara now has a much better prognosis than her mother who needed much more invasive treatment for her own breast cancer. “It’s a life saver, it’s a life changer,” she said.

Dr Gerald Lip, who led the prospective trial at NHS Grampian said, “If you pick up cancer under 15mm, most women now will have a 95% survival rate. Not only did Mia help us find more cancers, most of which were invasive and high grade, but we also modelled that it could reduce the time it takes to notify women from 14 days to just 3 days, reducing significant stress and anxiety for our patients.”

Professor Lesley Anderson, Chair in Health Data Science at the University of Aberdeen, said, “While our earlier research, led by Dr De Vries, suggested that Mia could spot more cancers, the GEMINI trial results left us amazed. If Mia were used in breast screening, it would mean that more cancers would be detected without putting more women through additional tests.”

“However, our previous research pointed out a possible issue—changes to the mammography machines could affect how well Mia works,” she said. “To smoothly integrate Mia into screening programs, we are working closely with Kheiron to develop ways to monitor and adjust the AI, ensuring it continues delivering the impressive results we saw in the recent evaluation.”

Operating as a medical device in Microsoft’s Azure Cloud, the Kheiron solution gives hospitals or breast screening centres that have internet connectivity the ability to use Mia to read mammograms and help radiologists make the critical decision in breast screening: to reassure a woman that her mammogram is normal or call her back for further investigation.

“Hearing directly from a woman whose cancers were picked up by Mia was momentous for everyone who has helped us pioneer the development and evaluation of our AI technology,” said Peter Kecskemethy, CEO of Kheiron. “These outstanding results have exceeded our expectations and we are so grateful to the teams from NHS Grampian, the University of Aberdeen, Microsoft and the UK Government who have enabled us to conduct this groundbreaking work.”

Identifiable patient data is removed before a mammogram is uploaded to the Azure Cloud. Once de-identified, the Mia software reads the mammogram and sends the recommendation back to the hospital or clinic. It is currently deployed at 4 sites in Europe and 16 NHS sites in the UK as part of ongoing trials.

This wide-scale deployment leveraging the Azure Cloud is part of the UK Government’s ambition to be at the forefront of AI technology in healthcare. In 2020, Jacob West, Managing Director of Healthcare and Life Sciences at Microsoft UK, said, “AI has the ability to transform every industry, but there is perhaps no more powerful case than in healthcare, which impacts us all throughout our lives. We believe that AI, in partnership with clinicians, can play a vital role in improving patient outcomes and the results of the prospective evaluation at NHS Grampian are clear evidence. Thanks to this pioneering work, more women have a greater chance of beating cancer.”

21st March 2024

12% more breast cancers detected with potential workload savings of 30% in the UK’s first prospective evaluation of breast screening AI

“It’s a lifesaver, it’s a life changer,” says one of the first women in the UK to have her breast cancer picked up by Kheiron Medical’s technology called Mia® An artific...

Abstract

4th January 2023

Abstract: Post-market real-world data demonstrating use of an AI system as an extra reader to augment breast cancer detection without unnecessary recalls

Purpose To demonstrate real-world post-market benefit of artificial intelligence (AI) as an extra reader in breast cancer screening (BCS). Method A commercially available AI system...

Abstract

4th January 2023

Abstract: Safe and effective integration of AI as supporting reader in double reading breast cancer screening

Purpose To evaluate the effectiveness and practical implications of a novel workflow of using AI as a supporting reader for the detection of breast cancer in double reading screeni...

Abstract

4th January 2023

Abstract: On the importance of including unconfirmed cases when assessing the effect of AI on the recall rate in breast cancer screening

Purpose To demonstrate the importance of using representative data, including unconfirmed cases (neither positive nor negative) to assess recall rate (RR) and avoid obscuring real-...

28th November 2022

NHS Grampian is working with Kheiron Medical Technologies, University of Aberdeen and Microsoft to support breast cancer detection

NHS Grampian, which provides health and social care services to more than 500,000 people in Scotland, is trialling Kheiron Medical Technologies’ artificial intelligence to help ...

28th November 2022

Gateshead Health Foundation NHS Trust furthers its partnership with Kheiron Medical Technologies under the NHS AI in Health & Care Award

In October 2021, Gateshead Health Foundation NHS Trust entered into a research agreement with Kheiron Medical Technologies as part of the NHS Artificial Intelligence (AI) in Health...

11th May 2022

Kheiron Forms US Breast Medical Advisory Board; Appoints Three Leaders With Deep Track Record Advocating For Women’s Health

Dr. Wendy DeMartini, Dr. Elizabeth Morris, and Dr. Amy Patel are trailblazers at the forefront of introducing innovative breast imaging technologies into clinical practice (London ...

4th May 2022

InHealth signs up to AI Award with Kheiron

InHealth, who provide services for North and East Devon NHS Breast Screening, has entered into the research agreement to work with Kheiron Medical Technologies as part of the AI in...

9th March 2022

Kheiron included in Fast Company’s Most Innovative Companies 2022 list

This AI cancer diagnostics company joins the ranks of Canva, Microsoft, SpaceX, and other winning companies that are changing lives for the better (London – March 9, 20...

1 2 3 … 8 Next »